BPC-157 vs ARA-290 (Cibinetide)
Side-by-Side Comparison
| Attribute | Bpc 157 | Ara 290 |
|---|---|---|
| Category | Healing & Recovery | Tissue Repair / Neuropathic Pain |
| Mechanism | BPC-157 acts through multiple overlapping pathways. It promotes angiogenesis by upregulating VEGFR2 and VEGF expression, and activates nitric oxide synthesis via the Src kinase-caveolin-1 pathway and... | ARA-290 selectively binds the innate repair receptor (IRR), a heteromeric complex of the erythropoietin receptor (EPOR) and β-common receptor (CD131/βcR). |
| Evidence Rating | C — Phase I–II Clinical Trials | C — Phase I–II Clinical Trials |
| Clinical Status | Research-only / No approved human indication. Phase I oral safety trial completed; Phase II UC trial underway. | Phase II clinical trials completed for sarcoidosis neuropathy, diabetic neuropathy, and corneal nerve repair. FDA Orphan Drug Designation granted. Not yet approved. |
| Safety Profile | No completed randomized controlled human clinical trials for safety assessment; Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology | Well-tolerated in all completed Phase II trials with no serious drug-related adverse events reported; No erythropoietic stimulation — no increase in hemoglobin, hematocrit, or thrombotic risk |
| Molecular Weight | ~1419.5 g/mol | ~1257 g/mol |
| Half-Life | ~15 min IV (animal data); oral activity persists 24+ hours | ~2 minutes (plasma); tissue-level effects persist 24–72 hours |
Overview
BPC-157 and ARA-290 (Cibinetide) are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
BPC-157 — Mechanism & Evidence
BPC-157 is a synthetic 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.5 g/mol) derived from a protein found in human gastric juice. It has demonstrated robust regenerative and cytoprotective effects across hundreds of animal studies spanning tendon, ligament, muscle, bone, nerve, GI tract, and blood vessel healing. However, human clinical data is extremely limited — only three pilot studies have examined BPC-157 in humans as of 2025 (knee pain n=16, interstitial cystitis n=12, IV safety n=2). The FDA classifies it as Category 2, prohibiting compounding, and WADA bans its use in sports.
Key claims: Accelerates tendon and ligament healing; Heals gut lining and treats leaky gut; Reverses NSAID-induced GI damage.
ARA-290 (Cibinetide) — Mechanism & Evidence
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide (MW ~1257 g/mol) derived from the helix B surface of erythropoietin (EPO). Unlike recombinant EPO, ARA-290 does not bind the classical EPO receptor homodimer and therefore does not stimulate erythropoiesis (red blood cell production), avoiding the thrombotic and cardiovascular risks of EPO. Instead, it selectively activates the innate repair receptor (IRR), a heterodimer of EPOR and β-common receptor (CD131), expressed on tissues undergoing stress or damage. ARA-290 received FDA Orphan Drug Designation for treatment of sarcoidosis-associated small fiber neuropathy. Multiple Phase II clinical trials have been completed demonstrating improvements in neuropathic pain, autonomic function, and corneal nerve fiber regeneration.
Key claims: Reduces neuropathic pain in sarcoidosis; Promotes corneal nerve fiber regeneration; Improves metabolic markers in type 2 diabetes.
Shared Research Applications
Both peptides are studied for: Injury Recovery.
BPC-157 is also researched for: Gut Health.
ARA-290 (Cibinetide) is also researched for: no additional unique applications.
Safety Considerations
BPC-157: No completed randomized controlled human clinical trials for safety assessment Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology FDA previously classified BPC-157 as Category 2 (significant safety concerns); removed from Category 2 on April 15, 2026. PCAC review pending July 2026 to determine compounding eligibility. FDA noted insufficient human safety data and potential immunogenicity risks.
ARA-290 (Cibinetide): Well-tolerated in all completed Phase II trials with no serious drug-related adverse events reported No erythropoietic stimulation — no increase in hemoglobin, hematocrit, or thrombotic risk Most common adverse events: mild injection site reactions, transient headache
Related Products
Related Research News
BPC-157 Gut Health: Gastric Cytoprotection Studies
Research on BPC-157 began with gastric cytoprotection in the early 1990s, led by Sikiric and colleagues at the University of Zagreb. Studies show it protects against ethanol-induced lesions and NSAID damage in rat models, with effects linked to angiogenesis, prostaglandins, nitric oxide, and gut-brain signaling. This body of work highlights its stability for oral use and broad preclinical applications in GI models.
BPC-157 Shelf Life: Lyophilized vs Reconstituted Stability Guide
BPC-157 has a finite shelf life that varies by form and storage. Lyophilized powder lasts 12-18 months refrigerated or 24+ months frozen, while reconstituted solution holds for about 28 days under refrigeration. Factors like temperature, light, and handling influence stability, and researchers should watch for signs of degradation to ensure reliable results.
BPC-157 + TB-500 Peptide Blend: Research on Healing and Repair
The BPC-157 and TB-500 peptide blend draws attention in research for potential synergy in tissue repair, angiogenesis, and reducing inflammation. BPC-157, a 15-amino-acid synthetic peptide, interacts with growth factors in preclinical models. TB-500, a 43-amino-acid analog of Thymosin Beta-4, supports cell migration and regeneration. Studies explore their roles in wound healing, tendon recovery, and more.